A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
A Phase 2, Single Center, Open-Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Daily Subcutaneously Administered ELX-02 in Patients With Nephropathic Cystinosis Bearing One or More CTNS Gene (Cystinosin) Nonsense Mutations
Sponsor: Eloxx Pharmaceuticals, Inc.
Terminated
Due to study design limitations, this study has been discontinued and will not proceed with the 2nd cohort as contemplated in the original protocol.
Other terminated trials from Eloxx Pharmaceuticals, Inc.
More terminations from Eloxx Pharmaceuticals, Inc.
This PHASE2 trial investigates Cystinosis and Genetic Disease and is currently terminated or withdrawn. Eloxx Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2020 — Nov 2020 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eloxx Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .